Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today, February 24, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year
Ionis to hold full year 2021 financial results webcast
Webcast scheduled for Thursday, February 24 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 10, 2022 /PRNewswire/ – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, February 24 th at 11:30 a.m.
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
NEW YORK and CARLSBAD, Calif. , Jan. 31, 2022 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer -led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
CARLSBAD, Calif. , Jan. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
CARLSBAD, Calif. , Jan. 19, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it to become a leading, fully integrated biotechnology company. Joseph T.